RA Capital Management Decreases Position in Werewolf Therapeutics via Open Market Sales

On May 14, 2026, RA Capital Management, L.P., along with Peter Kolchinsky and Rajeev Shah, filed Amendment No. 8 to their Schedule 13D regarding Werewolf Therapeutics, Inc. (HOWL). The filing reports that the reporting persons collectively hold 6,116,140 shares of Common Stock, representing 12.6% of the class based on shares outstanding as of May 1, 2026. This position includes 5,709,858 shares held by RA Capital Healthcare Fund, L.P. and 406,282 shares held by RA Capital Nexus Fund II, L.P. Between May 8 and May 12, 2026, the funds executed a series of open market sales totaling 565,167 shares at weighted average prices ranging from $0.64 to $0.71 per share. Despite these sales, the reported ownership percentage reflects an increase compared to previous filings due to changes in the issuer's total outstanding share count. RA Capital Management serves as the investment adviser for the funds, with Kolchinsky and Shah acting as controlling persons.